Lineage Cell Therapeutics, Inc.
Company Stats
- Market Cap
- $241.7M
- as of Sep 30, 2026
- Shares Outstanding
- 252.9M
- Free Float
- 46.2%
Income Statement
- Revenue
- $14.6M
- Operating Income
- -$36.6M
- Net Income
- -$63.5M
- EBITDA
- -$35.9M
- Non-cash Impairment
- $14.8M
- Revenue Growth, 3Y
- -0.3%
- FCF Margin, 3Y Avg
- -236.5%
- FCF Margin, Worst Year
- -326.9%
Cash Flow
- Free Cash Flow
- -$19.4M
- FCF Yield
- -8.0%
- Owner FCF Yield
- -10.0%
Balance Sheet
- Cash & Equivalents
- $40.8M
Returns & Capital
- SBC, 3Y Avg
- $4.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $14.6M | -$19.4M | -133.6% |
| FY2024 | $9.5M | -$23.7M | -249.0% |
| FY2023 | $8.9M | -$29.2M | -326.9% |
| FY2022 | $14.7M | $646,000 | 4.4% |
| FY2021 | $4.3M | -$23.9M | -550.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back